A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

• Drug: PF-04455242
  
  Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
• Drug: Placebo
  
  PIC matching in appearance to PF-04455242 will be used to administer placebo.

• Active Comparator: Treatment
  
  2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
  Intervention: Drug: PF-04455242
• Placebo Comparator: Placebo
  
  2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
  Intervention: Drug: Placebo

Inclusion Criteria:

• Healthy male and/or female of non-childbearing potential between the ages of 18 and 55 years.
• Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (>110 lbs).
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

• Evidence or history of clinically significant medical condition or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening).
• Use of tobacco- or nicotine-containing products within 3 months of screening or a positive urine or blood cotinine at screening.
• A positive urine drug screen. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men.